Conference Presentation Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Developing the Next Generation of Immunotherapeutic Strategies for Solid Tumors

Release Date: June 24, 2009| Expiration Date: June 24, 2010
May 30, 2009, Orlando, FL

Lecture Overview

This on-demand Webcast is from a satellite symposium held in conjunction with the 45th Annual Meeting of the American Society of Clinical Oncology held on May 29-June 2, 2009, in Orlando, FL.

The Developing the Next Generation of Immunotherapeutic Strategies for Solid Tumors symposium is designed to provide participants with cutting-edge information on the development of cancer immunotherapy. Harnessing the specificity of the patient’s immune system, vaccines, and immunotherapies are potentially the ultimate targeted agents, and this program will review the immunobiology of cancer vaccines and the refinement of approaches to optimize the activity of vaccines. Internationally recognized experts will review vaccines and immunotherapeutic agents in development for lung cancer, melanoma, and prostate cancer. An expert panel discussion will address key questions to improve clinical investigation of therapeutic cancer vaccines. This program will conclude with a look at late-breaking and upcoming clinical data on immunotherapy for patients with cancer.

This educational activity is directed toward medical oncologists involved in the care of patients with solid tumors. Fellows, nurses, physician assistants, and pharmacists are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Discuss the principles of using vaccines to stimulate antitumor activity of a patient’s immune system
  • Assess the efficacy and safety of vaccines in development for patients with non–small-cell lung cancer
  • Describe immunotherapeutic approaches under investigation for patients with melanoma
  • Compare various approaches to induce cytotoxic response to tumors in patients with prostate cancer
  • Identify clinical trials for therapeutic cancer vaccines in patients with solid tumors

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentations and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

View the Activity
You will be asked to login
or create an account.

Educational Grants

An educational grant for this activity was provided by:


  1. Bristol-Myers Squibb
  2. Provectus Pharmaceuticals, Inc.